Compugen (NASDAQ:CGEN – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “buy” rating to a “hold” rating in a note issued to investors on Wednesday. Separately, ...

Truist Financial analyst Asthika Goonewardene maintained a Buy rating on Compugen (CGEN – Research Report) today. The company’s shares closed ...

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses on ...

Compugen (NASDAQ:CGEN – Get Free Report) is anticipated to issue its quarterly earnings data before the market opens on Tuesday, March 4th. Analysts expect the company to announce earnings of $0.07 ...

Compugen's innovative approach targets under-explored immune pathways like PVRIG and IL-18 binding protein, offering potential upside, despite current market skepticism. With $113.2 million in ...

The projected fair value for Compugen is US$1.92 based on 2 Stage Free Cash Flow to Equity Current share price of US$1.81 suggests Compugen is potentially trading close to its fair value Our fair ...

Compugen is driving the discovery and development of cancer immunotherapy drugs using its proprietary computational solutions, advanced new omics technologies and integration of computational ...

Compugen (CGEN) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of $0.07. This compares to earnings of $0.11 per share a year ago. These figures are adjusted for ...

Compugen (CGEN) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of $0.07. This compares to earnings of $0.11 per share a year ago. These figures are adjusted ...